» Articles » PMID: 35663045

Association Between Rheumatoid Arthritis Disease Activity and Risk of Ovarian Malignancy in Middle-Aged and Elderly Women

Overview
Journal Biomed Res Int
Publisher Wiley
Date 2022 Jun 6
PMID 35663045
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To investigate the risk of ovarian malignancy in middle-aged and elderly women with rheumatoid arthritis (RA) and its correlation with disease activity.

Methods: 219 middle-aged and elderly (age ≥ 40) female RA patients who were treated at the Department of Rheumatology and Immunology of the Second Affiliated Hospital of Guizhou University of Traditional Chinese Medicine from August 2019 to September 2020 were selected. Their general information such as age and medical history was collected. RA disease activity-related indicators include rheumatoid factor (RF), anticyclic citrullinated peptide antibody (ACPA), ESR, CRP, and ovarian malignancy risk-related indicators including alpha fetoprotein (AFP), carcinoembryonic antigen (CEA), CA125, CA199, and human epididymis protein 4 (HE4) were detected. According to Risk of Ovarian Malignancy Algorithm (ROMA), they were divided into a low-risk group (ROMA-low, premenopausal: ROMA ≤ 11.4%, postmenopausal: ROMA ≤ 29.9%) and a high-risk group (ROMA-high, premenopausal: ROMA > 11.4%, postmenopausal: ROMA > 29.9%) for ovarian malignancy. Meanwhile, according to the DAS28-ESR, they were divided into the general disease activity group (DAS28-ESR ≤ 5.1) and the high disease activity group (DAS28-ESR > 5.1). SPSS 25.0 software was used to compare the differences among groups and to analyze the correlation between ovarian malignancy risk and RA disease activity.

Results: Compared with the ROMA-low group, the levels of RF, ACCP, CDAI, SDAI, DAS28-ESR, and DAS28-CRP in the ROMA-high group were significantly increased ( < 0.05). HE4 and ROMA in the high disease activity group were significantly higher than general disease activity group ( < 0.05). Spearman correlation analysis showed that age ( = 0.472), RF ( = 0.221), ACPA ( = 0.156), CDAI ( = 0.226), SDAI ( = 0.221), DAS28-ESR ( = 0.254), DAS28-CRP ( = 0.208), medications ( = 0.189), and CA199 ( = 0.250) were correlated with ROMA ( < 0.05). Multivariate regression analysis showed that ESR (OR = 1.11), SDAI (OR = 1.02), DAS28-ESR (OR = 1.33), DAS28-CRP (OR = 1.26), and CA199 (OR = 1.03) were independent risk factors for high risk of ovarian malignancy ( < 0.05). Subgroup analysis showed that CA199 is an effect modification factor for DAS28-ESR ( < 0.05).

Conclusion: The risk of ovarian malignancy is significantly increased in middle-aged and elderly women with high disease activity with rheumatoid arthritis. In clinical, full attention should be paid to the risk of ovarian malignancy in this population. Screening in time, especially in patients with increased DAS28-ESR and CA199 at the same time, is needed.

Citing Articles

The Genetic Causal Effect of Autoimmune Diseases on pan-Cancers: Evidence from Mendelian Randomization.

Long Y, Pan Y, Yang H, Wang X, Jiang Z, Sun T J Cancer. 2025; 16(2):567-576.

PMID: 39744497 PMC: 11685688. DOI: 10.7150/jca.103693.


The association between three prevalent autoimmune disorders and the likelihood of developing prostate cancer: a Mendelian randomization study.

Deng X, Sun S, Yao W, Yue P, Guo F, Wang Y Sci Rep. 2024; 14(1):11755.

PMID: 38783043 PMC: 11116512. DOI: 10.1038/s41598-024-62716-6.


The genetic liability to rheumatoid arthritis may decrease hepatocellular carcinoma risk in East Asian population: a Mendelian randomization study.

Zhang Y, Zhang Y, He P, Ge F, Huo Z, Qiao G Arthritis Res Ther. 2023; 25(1):49.

PMID: 36973792 PMC: 10041783. DOI: 10.1186/s13075-023-03029-3.

References
1.
Nebgen D, Lu K, Bast Jr R . Novel Approaches to Ovarian Cancer Screening. Curr Oncol Rep. 2019; 21(8):75. PMC: 6662655. DOI: 10.1007/s11912-019-0816-0. View

2.
Romagnolo C, Leon A, Fabricio A, Taborelli M, Polesel J, Pup L . HE4, CA125 and risk of ovarian malignancy algorithm (ROMA) as diagnostic tools for ovarian cancer in patients with a pelvic mass: An Italian multicenter study. Gynecol Oncol. 2016; 141(2):303-311. DOI: 10.1016/j.ygyno.2016.01.016. View

3.
Hellgren K, Baecklund E, Backlin C, Sundstrom C, Smedby K, Askling J . Rheumatoid Arthritis and Risk of Malignant Lymphoma: Is the Risk Still Increased?. Arthritis Rheumatol. 2016; 69(4):700-708. DOI: 10.1002/art.40017. View

4.
Lim X, Xiang W, Tan J, Koh L, Lian T, Leong K . Incidence and patterns of malignancies in a multi-ethnic cohort of rheumatoid arthritis patients. Int J Rheum Dis. 2019; 22(9):1679-1685. DOI: 10.1111/1756-185X.13655. View

5.
Zhu C, Zhu J, Qian L, Liu H, Shen Z, Wu D . Clinical characteristics and prognosis of ovarian clear cell carcinoma: a 10-year retrospective study. BMC Cancer. 2021; 21(1):322. PMC: 7993454. DOI: 10.1186/s12885-021-08061-7. View